Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Newly Diagnosed Acute Myeloid Leukemia (AML)~* Considered inappropriate for intensive remission induction therapy by an investigator~* Not eligible for stem cell transplantation~Exclusion Criteria:~* Acute promyelocytic leukemia~* Current Myelodysplastic syndrome only subjects~* Unstable angina or uncontrolled congestive heart failure~* Any other malignancy, excluding basal or squamous cell carcinoma of the skin, in situ melanoma, cervical carcinoma in situ, localized prostate cancer, or superficial bladder cancer stage 0, from which the subject has not been disease-free for at least 3 years~* Respiratory disease requiring continuous supplemental oxygen~Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ulocuplumab + low dose Cytarabine (Type: EXPERIMENTAL): Ulocuplumab + low dose Cytarabine (LDAC) Phase 1 (escalation cohort) - closed for enrollment
- Ulocuplumab Dose A + low dose Cytarabine (Type: EXPERIMENTAL): Ulocuplumab Dose A + low dose Cytarabine Phase 2 (expansion cohort)
- Ulocuplumab Dose B + low dose Cytarabine (Type: EXPERIMENTAL): Ulocuplumab Dose B + low dose Cytarabine Phase 2 (expansion cohort)
- low dose Cytarabine only (Type: OTHER): Low Dose Cytarabine only Phase 2 (expansion cohort)

Based on this trial design, predict the completion outcome and termination type (if applicable).